Alembic Pharmaceuticals Reports 29.20% Increase in Net Profit for Q1 2026
Alembic Pharmaceuticals consolidated net profit rises 29.20% in the March 2026 quarter
Image: Business Standard
Alembic Pharmaceuticals reported a 29.20% increase in net profit, reaching ₹202.70 crore for the quarter ending March 2026, compared to ₹156.89 crore in the same quarter last year. Sales also rose by 4.41% to ₹1847.72 crore during this period.
- 01Net profit for the full year increased by 15.66% to ₹674.77 crore compared to ₹583.42 crore in the previous year.
- 02Annual sales for the year ended March 2026 rose by 10.08% to ₹7344.90 crore.
- 03The operating profit margin (OPM) for the quarter was 12.34%, down from 15.33% in the previous year.
- 04Profit before tax (PBT) for the quarter was ₹143.38 crore, a decline of 25% from ₹191.94 crore last year.
- 05The company saw a 4.41% increase in sales compared to the previous quarter.
Advertisement
In-Article Ad
Alembic Pharmaceuticals has reported a robust 29.20% increase in net profit for the quarter ending March 2026, amounting to ₹202.70 crore, compared to ₹156.89 crore in the same quarter the previous year. Sales also saw an uptick of 4.41%, reaching ₹1847.72 crore. For the full financial year, the company recorded a 15.66% rise in net profit, totaling ₹674.77 crore, and a 10.08% increase in sales, which amounted to ₹7344.90 crore. Despite these gains, the operating profit margin (OPM) fell to 12.34%, down from 15.33% a year earlier, indicating some pressure on profitability. Profit before tax (PBT) for the quarter was reported at ₹143.38 crore, reflecting a 25% decline from the previous year.
Advertisement
In-Article Ad
The increase in net profit and sales indicates a positive financial performance for Alembic Pharmaceuticals, which could lead to potential job growth and investment in the local economy.
Advertisement
In-Article Ad
Reader Poll
How do you view Alembic Pharmaceuticals' financial growth?
Connecting to poll...
More about Alembic Pharmaceuticals
Alembic Pharmaceuticals Shares Drop 9% Amid Weak Q4 Results
Business Standard • May 18, 2026
Alembic Pharmaceuticals Reports 29% Increase in Q4 Profit, Launches New Products
Business Standard • May 15, 2026
Alembic Pharmaceuticals Gains USFDA Tentative Approval for Darolutamide Tablets
Business Standard • May 14, 2026
Read the original article
Visit the source for the complete story.